Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Thalassemia Major With Severe Transfusional Iron Overload”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Large-scale testing (Phase 3)UnknownNCT01511848
What this trial is testing

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Who this might be right for
Beta-thalassemia MajorSickle Cell DiseaseIron Hemosiderosis
Ain Shams University 60
Testing effectiveness (Phase 2)Study completedNCT01709032
What this trial is testing

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Who this might be right for
Thalassemia Major With Severe Transfusional Iron Overload
Children's Hospital of Philadelphia 9
Testing effectiveness (Phase 2)Study completedNCT01044186
What this trial is testing

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Who this might be right for
Transfusional Iron Overload
Novartis Pharmaceuticals 30
Large-scale testing (Phase 3)Study completedNCT00171171
What this trial is testing

Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Who this might be right for
Beta-ThalassemiaHemosiderosis
Novartis 252
Testing effectiveness (Phase 2)Study completedNCT00390858
What this trial is testing

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Who this might be right for
Transfusional Iron Overloadβ-thalassemia MajorPediatric Rare Anemia
Novartis Pharmaceuticals 40
Post-approval studies (Phase 4)Study completedNCT00171301
What this trial is testing

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Who this might be right for
Beta-thalassemia MajorHemosiderosisIron Overload+1 more
Novartis Pharmaceuticals 233